olatorepatide

Peptide

Also known as HS-20094

Filedunder review

Evidence outlook · regulatory review

Obesity: application under NMPA review

NMPA accepts olatorepatide NDA (2026-06). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

NCT06839664: This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Also in development:Type 2 Diabetes · Phase 3Hidradenitis Suppurativa · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Obesity
NCT07896265 · Regeneron Pharmaceuticals
2026-11-18 – 2029-01-23 · Overweight or Obesity Without Diabetes
What this study did
Type 2 Diabetes
Phase 2 (6)
Hidradenitis Suppurativa
NCT07830329 · Regeneron Pharmaceuticals
2026-10-29 – 2028-12-22 · Hidradenitis Suppurativa
What this study did
Obesity
NCT06118021 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2023-10-16 – 2024-08-13 · Overweight and Obesity
What this study did
Type 2 Diabetes
NCT06901648 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2024-02-06 – 2025-04-09 · Type 2 Diabetes
What this study did
NCT06118008 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2023-05-31 – 2024-01-04 · Type 2 Diabetes
What this study did
Phase 1 (2)
Obesity
NCT07057674 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-04-16 – 2026-05-29 · Overweight or Obesity
What this study did
Type 2 Diabetes
NCT05116410 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2021-11-01 – 2022-12-31 · Type 2 Diabetes
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, 2 of them ahead of this one.

This drug's own stage for Hidradenitis Suppurativa: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Olatorepatide: this drugPhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FPartial signal
NCT04242498: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results).
NCT04242446: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Partial signal
NCT03713632: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): AIN457 Q2W 42.3 Percentage of Participants | AIN457 Q4W 46.1 Percentage of Participants | Placebo 31.2 Percentage of Participants
NCT03713619: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): Secukinumab 1 - Q2W 45 Percentage of participants | Secukinumab 2 - Q4W 41.8 Percentage of participants | Placebo 33.7 Percentage of participants
LutikizumabPhase 3Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
RemibrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Opzelura)Phase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2/3Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
Spesolimab (Spevigo)Phase 2/3Monoclonal antibodyIL-36 receptornot yet gradedNo reviewed efficacy summary in this indication
AbdakibartPhase 2Monoclonal antibodyIL-1 betanot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
EltrekibartPhase 2Monoclonal antibodyCXCR1/2not yet gradedNo reviewed efficacy summary in this indication
ORKA-002Phase 2Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
SAR442970Phase 2——not yet gradedNo reviewed efficacy summary in this indication
SAR445399Phase 2Monoclonal antibodyIL-1R3 (IL1RAP)not yet gradedNo reviewed efficacy summary in this indication
SPY072Phase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
ZasocitinibPhase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ABBV-1451
Phase 1(overall)
UndisclosedIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
KP405
Phase 1(overall)
PeptideGLP-1/GIP receptor (dual)
Partial signal(overall)
No reviewed efficacy summary in this indication
SAR447971
Phase 1(overall)
Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
TipasertidegDiscontinuedSmall moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication

Compare side by side

5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow olatorepatide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (2)
Phase 3Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-03-30 · NCT07156500 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-03-30 · NCT07156539 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 2ObesityRecruiting
Est. primary completion 2028-01-21 · NCT07685808 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2ObesityRecruiting
Est. primary completion 2028-11-24 · NCT07830329 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2028-12-19 · NCT07896265 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

June 2026Filing acceptedNMPA accepts olatorepatide NDA
CN, NMPA · Hansoh Pharma · Source ↗
9 March 2026Topline resultPositive Phase 3 topline results for olatorepatide in Chinese adults with obesity
7 March 2026Topline resultPhase 3 study of olatorepatide (HS-20094) in China met its co-primary endpoints at week 48
CN · Hansoh Pharma · Source ↗